Venous thromboembolism risk up with cisplatin-based chemo

November 15, 2012
Venous thromboembolism risk up with cisplatin-based chemo
Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event compared with those who do not receive a cisplatin-based regimen, according to research published online Nov. 13 in the Journal of Clinical Oncology.

(HealthDay)—Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event (VTE) compared with those who do not receive a cisplatin-based regimen, according to research published online Nov. 13 in the Journal of Clinical Oncology.

To evaluate the incidence and risk of VTEs associated with cisplatin-based chemotherapy, Sonia Seng, M.D., of the Southcoast Centers for Cancer Care in Fairhaven, Mass., and colleagues conducted a systematic review and meta-analysis of 38 from 1990 to 2010 involving 8,216 patients with various advanced solid tumors.

The researchers found that the incidence of VTEs in patients treated with cisplatin-based chemotherapy was 1.92 percent, compared with 0.79 percent in patients who did not receive cisplatin-based regimens. Cisplatin-based therapy was associated with significantly increased risk of a VTE (relative risk [RR], 1.67). Patients receiving a weekly equivalent cisplatin dose greater than 30 mg/m² had the highest risk (RR, 2.71), and increased risks were also noted for patients in trials during 2001 to 2010 (RR, 1.72).

"We observed a 1.67-fold increase in the risk of VTEs with cisplatin as compared with non-cisplatin-based chemotherapy," the authors write. "Given the morbidity and mortality associated with VTEs in patients with cancer, our study adds further support to calls for prospective trials of -based chemotherapy administered with prophylactic anticoagulation."

Several authors disclosed to the pharmaceutical industry.

Explore further: Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

January 26, 2012
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to ...

New biomarker for common lung cancer predicts responses to chemotherapy

July 26, 2012
Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published ...

Curcumin compound improves effectiveness of head and neck cancer treatment

May 19, 2011
A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived ...

'DIMming' cancer growth -- STAT: Diindolylmethane suppresses ovarian cancer

January 26, 2012
Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane ...

Researchers investigate drug resistant ovarian cancer to improve clinical treatment

August 9, 2012
(Medical Xpress) -- A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.